f | { | f | { |
| "author": "", | | "author": "", |
| "author_email": "cmkandawire@hivmw.org", | | "author_email": "cmkandawire@hivmw.org", |
| "creator_user_id": "c64e3919-2d1c-42bf-835b-e85a6be9792c", | | "creator_user_id": "c64e3919-2d1c-42bf-835b-e85a6be9792c", |
| "groups": [], | | "groups": [], |
| "id": "394f8196-2634-40b4-bd18-c9c12a7cdf16", | | "id": "394f8196-2634-40b4-bd18-c9c12a7cdf16", |
| "isopen": false, | | "isopen": false, |
| "license_id": "notspecified", | | "license_id": "notspecified", |
| "license_title": "License not specified", | | "license_title": "License not specified", |
| "maintainer": null, | | "maintainer": null, |
| "maintainer_email": null, | | "maintainer_email": null, |
| "metadata_created": "2022-08-30T09:24:05.615214", | | "metadata_created": "2022-08-30T09:24:05.615214", |
n | "metadata_modified": "2022-08-30T09:31:36.216332", | n | "metadata_modified": "2022-08-30T09:32:02.382867", |
| "name": "malawi-integrated-hiv-program-report-2021-q1", | | "name": "malawi-integrated-hiv-program-report-2021-q1", |
| "notes": "__Program performance highlights by the end of March 2021 | | "notes": "__Program performance highlights by the end of March 2021 |
| include:__\r\n\r\n* Scale-up of integrated HIV services had reached | | include:__\r\n\r\n* Scale-up of integrated HIV services had reached |
t | the following number of sites:\r\n * __724__ static and | t | the following number of sites:\r\n \r\n * |
| __154__ outreach HIV testing sites.\r\n * __ 760__ | | __724__ static and __154__ outreach HIV testing sites.\r\n |
| (static) ART sites; __605__ of these started at least one pregnant or | | * __ 760__ (static) ART sites; __605__ of these started at least one |
| breastfeeding woman.\r\n * __699__ sites with HIV-exposed | | pregnant or breastfeeding woman.\r\n * __699__ sites with |
| children in follow-up.\r\n* 670,567 persons were tested for HIV by a | | HIV-exposed children in follow-up.\r\n* 670,567 persons were tested |
| trained provider and received their results;\r\n131,552 (20%) accessed | | for HIV by a trained provider and received their results;\r\n131,552 |
| HIV testing for the first time; 539,015 (80%) were repeat testers and | | (20%) accessed HIV testing for the first time; 539,015 (80%) were |
| 22,296 (4%) of these received confirmatory testing (after having | | repeat testers and 22,296 (4%) of these received confirmatory testing |
| tested positive in the past). 20,078 (3.1%) clients received a | | (after having tested positive in the past). 20,078 (3.1%) clients |
| positive result for the first time.\r\n* A total of 104,724 people | | received a positive result for the first time.\r\n* A total of 104,724 |
| received 173,272 self-test kits; 77,033 (44%) of these were for use by | | people received 173,272 self-test kits; 77,033 (44%) of these were for |
| the recipient and 96,239 (56%) for onward distribution to sex partners | | use by the recipient and 96,239 (56%) for onward distribution to sex |
| or other people.\r\n* 18,193 (97%) of 18,802 blood units collected | | partners or other people.\r\n* 18,193 (97%) of 18,802 blood units |
| were screened for (at least) HIV, hepatitis B and syphilis.\r\n* A | | collected were screened for (at least) HIV, hepatitis B and |
| cumulative total of 825 clients were referred for PrEP eligibility | | syphilis.\r\n* A cumulative total of 825 clients were referred for |
| screening and 544 (66%) were found eligible. 277 newly started PrEP | | PrEP eligibility screening and 544 (66%) were found eligible. 277 |
| and 177 clients were retained on PrEP at the end of the quarter.\r\n* | | newly started PrEP and 177 clients were retained on PrEP at the end of |
| 155,575 (99%) of 157,743 women at ANC had their HIV status | | the quarter.\r\n* 155,575 (99%) of 157,743 women at ANC had their HIV |
| ascertained;\r\n10,724 (7%) of these were HIV positive. 131,564 (95%) | | status ascertained;\r\n10,724 (7%) of these were HIV positive. 131,564 |
| of 139,169 at maternity had their HIV status ascertained 9,387 (7%) of | | (95%) of 139,169 at maternity had their HIV status ascertained 9,387 |
| these were HIV positive.\r\n* 19,682 patients started ART this | | (7%) of these were HIV positive.\r\n* 19,682 patients started ART this |
| quarter; 79% were classified as asymptomatic / in WHO stage 1 and | | quarter; 79% were classified as asymptomatic / in WHO stage 1 and |
| started under the \u201cTest & Treat\u201d policy.\r\n* 871,098 | | started under the \u201cTest & Treat\u201d policy.\r\n* 871,098 |
| patients were alive and on ART by end of March 2021.2 This means that | | patients were alive and on ART by end of March 2021.2 This means that |
| 88% of the estimated 986,671 HIV positive population was on ART. 3 ART | | 88% of the estimated 986,671 HIV positive population was on ART. 3 ART |
| coverage was 78% (44,960/ 57,530) for children4 and 89% (826,138 / | | coverage was 78% (44,960/ 57,530) for children4 and 89% (826,138 / |
| 929,141) for adults.\r\n* 136,281 (95%) of viral load results from | | 929,141) for adults.\r\n* 136,281 (95%) of viral load results from |
| routine monitoring were <1000 copies/ml.\r\nViral suppression rates | | routine monitoring were <1000 copies/ml.\r\nViral suppression rates |
| for routine samples among children (0-14 years) and adults (15+ years) | | for routine samples among children (0-14 years) and adults (15+ years) |
| were 77% and 96%, respectively.\r\n* 73% of adults and 76% of children | | were 77% and 96%, respectively.\r\n* 73% of adults and 76% of children |
| were retained alive on ART at 12 months after initiation.\r\n* Out of | | were retained alive on ART at 12 months after initiation.\r\n* Out of |
| 851,998 patients on first line adult ART 817,888 (97%) had | | 851,998 patients on first line adult ART 817,888 (97%) had |
| transitioned to TDF/3TC/DTG and only 4,388 (1%) were on TDF/3TC/EFV.", | | transitioned to TDF/3TC/DTG and only 4,388 (1%) were on TDF/3TC/EFV.", |
| "num_resources": 1, | | "num_resources": 1, |
| "num_tags": 9, | | "num_tags": 9, |
| "organization": { | | "organization": { |
| "approval_status": "approved", | | "approval_status": "approved", |
| "created": "2021-10-14T11:02:35.234558", | | "created": "2021-10-14T11:02:35.234558", |
| "description": "The Department of HIV & AIDS (DHA) was established | | "description": "The Department of HIV & AIDS (DHA) was established |
| in 2001, initially as a unit in the Department of Clinical Services, | | in 2001, initially as a unit in the Department of Clinical Services, |
| to coordinate the biomedical HIV Program in Malawi. The department now | | to coordinate the biomedical HIV Program in Malawi. The department now |
| carries responsibility for various HIV related programs including: | | carries responsibility for various HIV related programs including: |
| sexually transmitted infections (STIs), prevention of mother to child | | sexually transmitted infections (STIs), prevention of mother to child |
| transmission of HIV (PMTCT), and national voluntary male medical | | transmission of HIV (PMTCT), and national voluntary male medical |
| circumcision program (VMMC). All these HIV program sub-sections are | | circumcision program (VMMC). All these HIV program sub-sections are |
| linked to one robust monitoring and evaluation sub-section in the HIV | | linked to one robust monitoring and evaluation sub-section in the HIV |
| and AIDS Department which technically operates under the Central | | and AIDS Department which technically operates under the Central |
| Monitoring and Evaluation Department (CMED) of the Ministry of | | Monitoring and Evaluation Department (CMED) of the Ministry of |
| Health.", | | Health.", |
| "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | | "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", |
| "image_url": | | "image_url": |
| 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", | | 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", |
| "is_organization": true, | | "is_organization": true, |
| "name": "dha", | | "name": "dha", |
| "state": "active", | | "state": "active", |
| "title": "Department of HIV & AIDS and Viral Hepatitis", | | "title": "Department of HIV & AIDS and Viral Hepatitis", |
| "type": "organization" | | "type": "organization" |
| }, | | }, |
| "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | | "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", |
| "private": false, | | "private": false, |
| "program_area": "Care and Treatment", | | "program_area": "Care and Treatment", |
| "relationships_as_object": [], | | "relationships_as_object": [], |
| "relationships_as_subject": [], | | "relationships_as_subject": [], |
| "resources": [ | | "resources": [ |
| { | | { |
| "cache_last_updated": null, | | "cache_last_updated": null, |
| "cache_url": null, | | "cache_url": null, |
| "created": "2022-08-30T09:25:41.056469", | | "created": "2022-08-30T09:25:41.056469", |
| "description": "", | | "description": "", |
| "format": "PDF", | | "format": "PDF", |
| "hash": "", | | "hash": "", |
| "id": "2e4da787-ec50-4165-9b43-276da2c09912", | | "id": "2e4da787-ec50-4165-9b43-276da2c09912", |
| "last_modified": "2022-08-30T09:25:40.989527", | | "last_modified": "2022-08-30T09:25:40.989527", |
| "lfs_prefix": | | "lfs_prefix": |
| "dha/malawi-integrated-hiv-program-report-2021-q1", | | "dha/malawi-integrated-hiv-program-report-2021-q1", |
| "metadata_modified": "2022-08-30T09:25:41.222238", | | "metadata_modified": "2022-08-30T09:25:41.222238", |
| "mimetype": "application/pdf", | | "mimetype": "application/pdf", |
| "mimetype_inner": null, | | "mimetype_inner": null, |
| "name": "Malawi Integrated HIV Program Report 2021 Q1", | | "name": "Malawi Integrated HIV Program Report 2021 Q1", |
| "package_id": "394f8196-2634-40b4-bd18-c9c12a7cdf16", | | "package_id": "394f8196-2634-40b4-bd18-c9c12a7cdf16", |
| "position": 0, | | "position": 0, |
| "resource_type": null, | | "resource_type": null, |
| "sha256": | | "sha256": |
| "dc7b5ac9ec7c20486455365a29dc196043aa716965d2389fd607ee48ee6bf077", | | "dc7b5ac9ec7c20486455365a29dc196043aa716965d2389fd607ee48ee6bf077", |
| "size": 3600910, | | "size": 3600910, |
| "state": "active", | | "state": "active", |
| "url": | | "url": |
| 6da2c09912/download/malawi_integrated_hiv_program_report_2021_q1.pdf", | | 6da2c09912/download/malawi_integrated_hiv_program_report_2021_q1.pdf", |
| "url_type": "upload" | | "url_type": "upload" |
| } | | } |
| ], | | ], |
| "state": "active", | | "state": "active", |
| "tags": [ | | "tags": [ |
| { | | { |
| "display_name": "HTC", | | "display_name": "HTC", |
| "id": "6a53fcf5-e774-4295-b9c3-32da8b896f9b", | | "id": "6a53fcf5-e774-4295-b9c3-32da8b896f9b", |
| "name": "HTC", | | "name": "HTC", |
| "state": "active", | | "state": "active", |
| "vocabulary_id": null | | "vocabulary_id": null |
| }, | | }, |
| { | | { |
| "display_name": "PMTCT-ART", | | "display_name": "PMTCT-ART", |
| "id": "83bf82ef-383c-46e2-a80c-f3431b3f99e2", | | "id": "83bf82ef-383c-46e2-a80c-f3431b3f99e2", |
| "name": "PMTCT-ART", | | "name": "PMTCT-ART", |
| "state": "active", | | "state": "active", |
| "vocabulary_id": null | | "vocabulary_id": null |
| }, | | }, |
| { | | { |
| "display_name": "Report", | | "display_name": "Report", |
| "id": "37e5a5df-a993-4d3f-8c9c-73c418c30f0f", | | "id": "37e5a5df-a993-4d3f-8c9c-73c418c30f0f", |
| "name": "Report", | | "name": "Report", |
| "state": "active", | | "state": "active", |
| "vocabulary_id": null | | "vocabulary_id": null |
| }, | | }, |
| { | | { |
| "display_name": "anc", | | "display_name": "anc", |
| "id": "1e47aae6-8e3d-41e7-9b1a-778af0d2f23a", | | "id": "1e47aae6-8e3d-41e7-9b1a-778af0d2f23a", |
| "name": "anc", | | "name": "anc", |
| "state": "active", | | "state": "active", |
| "vocabulary_id": null | | "vocabulary_id": null |
| }, | | }, |
| { | | { |
| "display_name": "blood safety", | | "display_name": "blood safety", |
| "id": "24fd7907-18be-4ad1-80ad-ba65da6a9707", | | "id": "24fd7907-18be-4ad1-80ad-ba65da6a9707", |
| "name": "blood safety", | | "name": "blood safety", |
| "state": "active", | | "state": "active", |
| "vocabulary_id": null | | "vocabulary_id": null |
| }, | | }, |
| { | | { |
| "display_name": "hiv", | | "display_name": "hiv", |
| "id": "43013fde-ebf4-470e-9e5d-1a3aa939d404", | | "id": "43013fde-ebf4-470e-9e5d-1a3aa939d404", |
| "name": "hiv", | | "name": "hiv", |
| "state": "active", | | "state": "active", |
| "vocabulary_id": null | | "vocabulary_id": null |
| }, | | }, |
| { | | { |
| "display_name": "maternity", | | "display_name": "maternity", |
| "id": "cd2b6dc5-5d1f-4a03-91da-9a279e193ed2", | | "id": "cd2b6dc5-5d1f-4a03-91da-9a279e193ed2", |
| "name": "maternity", | | "name": "maternity", |
| "state": "active", | | "state": "active", |
| "vocabulary_id": null | | "vocabulary_id": null |
| }, | | }, |
| { | | { |
| "display_name": "sti", | | "display_name": "sti", |
| "id": "38222aa3-73ca-4ca8-8b42-9a5eb558af5a", | | "id": "38222aa3-73ca-4ca8-8b42-9a5eb558af5a", |
| "name": "sti", | | "name": "sti", |
| "state": "active", | | "state": "active", |
| "vocabulary_id": null | | "vocabulary_id": null |
| }, | | }, |
| { | | { |
| "display_name": "viral load", | | "display_name": "viral load", |
| "id": "e385a0a4-1722-431f-a657-f9616a14bf6f", | | "id": "e385a0a4-1722-431f-a657-f9616a14bf6f", |
| "name": "viral load", | | "name": "viral load", |
| "state": "active", | | "state": "active", |
| "vocabulary_id": null | | "vocabulary_id": null |
| } | | } |
| ], | | ], |
| "title": "Malawi Integrated HIV Program Report 2021 Q1", | | "title": "Malawi Integrated HIV Program Report 2021 Q1", |
| "type": "dataset", | | "type": "dataset", |
| "url": null, | | "url": null, |
| "version": null, | | "version": null, |
| "year": "2021" | | "year": "2021" |
| } | | } |